Specpharm is a South African pharmaceutical company which was established in April 2007. The company has two core business areas, 1) a manufacturing facility, where it manufactures and packages innovator and generic products for third party customers, and 2) a commercial business through which the company markets and sells generic and innovator products into South Africa and neighbouring countries.
Simeka currently owns 77% of the company, with the remaining equity held by management and staff.
The company is currently undergoing a fundraising exercise for expansion capital.